U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H12ClNO2S
Molecular Weight 329.801
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENTIAZAC

SMILES

OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3

InChI

InChIKey=JIEKMACRVQTPRC-UHFFFAOYSA-N
InChI=1S/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21)

HIDE SMILES / InChI
Molecular Formula C17H12ClNO2S
Molecular Weight 329.801
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Fentiazac is a non-steroidal anti-inflammatory agent developed for the treatment of pain disorders. The drug was marketed under the name Norvedan, however, its current marketing status is unknown and supposed to be "discontinued".

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
NORVEDAN

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2670 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3450 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4080 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1990 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1500 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1240 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.4 mg/L
CLINICAL TRIAL
https://pubmed.ncbi.nlm.nih.gov/8447848/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4490 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5200 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5670 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5770 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5510 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3400 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
CLINICAL TRIAL
https://pubmed.ncbi.nlm.nih.gov/8447848/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (grade 3, 5.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Disc. AE: Itching, Skin eruption...
AEs leading to
discontinuation/dose reduction:
Itching (grade 2, 5%)
Skin eruption (grade 2, 5%)
Epigastric pain (grade 2, 5%)
Headache (grade 2, 5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Disc. AE: Epigastric pain, Gastric ulcer...
AEs leading to
discontinuation/dose reduction:
Epigastric pain (6%)
Gastric ulcer (3%)
Liver function test abnormal (9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
AEs

AEs

AESignificanceDosePopulation
Rash grade 3, 5.3%
Disc. AE
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
Epigastric pain grade 2, 5%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Headache grade 2, 5%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Itching grade 2, 5%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Skin eruption grade 2, 5%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Gastric ulcer 3%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Epigastric pain 6%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Liver function test abnormal 9%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
PubMed

PubMed

TitleDatePubMed
Topical NSAIDs for acute pain: a meta-analysis.
2004-05-17
Patents

Patents

JP2003515526A
470

Sample Use Guides

In Vivo Use Guide
6,44 mg/kg as a daily dose.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:08:38 GMT 2025
Edited
by admin
on Mon Mar 31 18:08:38 GMT 2025
Record UNII
0YHF6E6NLS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENTIAZAC
INN   JAN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
NSC-282191
Preferred Name English
4-(P-CHLOROPHENYL)-2-PHENYL-5-THIAZOLEACETIC ACID
Common Name English
FENTIAZAC [USAN]
Common Name English
Fentiazac [WHO-DD]
Common Name English
FENTIAZAC [JAN]
Common Name English
fentiazac [INN]
Common Name English
FENTIAZAC [MART.]
Common Name English
5-THIAZOLEACETIC ACID, 4-(4-CHLOROPHENYL)-2-PHENYL-
Common Name English
WY-21894
Code English
FENTIAZAC [MI]
Common Name English
WY-21,894
Code English
Classification Tree Code System Code
WHO-ATC M02AA14
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
WHO-ATC M01AB10
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
WHO-VATC QM01AB10
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
NCI_THESAURUS C1323
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
WHO-VATC QM02AA14
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
241-958-1
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
MESH
C006124
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
NSC
282191
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
SMS_ID
100000081508
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
DRUG CENTRAL
1165
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
USAN
W-47
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
EVMPD
SUB07598MIG
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
PUBCHEM
28871
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL589092
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
WIKIPEDIA
FENTIAZAC
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
FDA UNII
0YHF6E6NLS
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
CAS
18046-21-4
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
INN
3710
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
NCI_THESAURUS
C81063
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID8023050
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
MERCK INDEX
m5300
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB13217
Created by admin on Mon Mar 31 18:08:38 GMT 2025 , Edited by admin on Mon Mar 31 18:08:38 GMT 2025
PRIMARY
Related Record Type Details
Structure of FENTIAZAC CALCIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of FENTIAZAC
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966